Jazz Pharma basks in praise as it adds CNS drugs in Azur acquisition #pharma #services

Posted On Dec 5 2017 by

#azur pharma # Jazz Pharma basks in praise as it adds CNS drugs in Azur acquisition Occasionally cited as a potential takeover target, Jazz Pharmaceuticals ($JAZZ) is in the news this morning with a takeover of its own. The biotech says it has struck an all-stock deal to acquire Dublin, Ireland-based Azur Pharma, adding new CNS drugs to its list of approved drugs. Once the proposed deal goes through, the combined operation is expected to have $475 million in annual revenue. Jazz CEO Bruce Cozadd told analysts this morning that the developer–which ran into a regulatory rejection last year–has been …


Jazz Pharma basks in praise as it adds CNS drugs in Azur acquisition #pharma #gossip

Posted On Nov 10 2017 by

#azur pharma # Jazz Pharma basks in praise as it adds CNS drugs in Azur acquisition Occasionally cited as a potential takeover target, Jazz Pharmaceuticals ($JAZZ) is in the news this morning with a takeover of its own. The biotech says it has struck an all-stock deal to acquire Dublin, Ireland-based Azur Pharma, adding new CNS drugs to its list of approved drugs. Once the proposed deal goes through, the combined operation is expected to have $475 million in annual revenue. Jazz CEO Bruce Cozadd told analysts this morning that the developer–which ran into a regulatory rejection last year–has been …


Jazz Pharma basks in praise as it adds CNS drugs in Azur acquisition #market #research #companies

Posted On Sep 10 2017 by

#azur pharma # Jazz Pharma basks in praise as it adds CNS drugs in Azur acquisition Occasionally cited as a potential takeover target, Jazz Pharmaceuticals ($JAZZ) is in the news this morning with a takeover of its own. The biotech says it has struck an all-stock deal to acquire Dublin, Ireland-based Azur Pharma, adding new CNS drugs to its list of approved drugs. Once the proposed deal goes through, the combined operation is expected to have $475 million in annual revenue. Jazz CEO Bruce Cozadd told analysts this morning that the developer–which ran into a regulatory rejection last year–has been …


Jazz Pharma basks in praise as it adds CNS drugs in Azur acquisition #vital #pharma

Posted On Aug 11 2017 by

#azur pharma # Jazz Pharma basks in praise as it adds CNS drugs in Azur acquisition Occasionally cited as a potential takeover target, Jazz Pharmaceuticals ($JAZZ) is in the news this morning with a takeover of its own. The biotech says it has struck an all-stock deal to acquire Dublin, Ireland-based Azur Pharma, adding new CNS drugs to its list of approved drugs. Once the proposed deal goes through, the combined operation is expected to have $475 million in annual revenue. Jazz CEO Bruce Cozadd told analysts this morning that the developer–which ran into a regulatory rejection last year–has been …


Jazz Pharma basks in praise as it adds CNS drugs in Azur acquisition #pharmaceutical #companies #in #atlanta

Posted On Jul 12 2017 by

#azur pharma # Jazz Pharma basks in praise as it adds CNS drugs in Azur acquisition Occasionally cited as a potential takeover target, Jazz Pharmaceuticals ($JAZZ) is in the news this morning with a takeover of its own. The biotech says it has struck an all-stock deal to acquire Dublin, Ireland-based Azur Pharma, adding new CNS drugs to its list of approved drugs. Once the proposed deal goes through, the combined operation is expected to have $475 million in annual revenue. Jazz CEO Bruce Cozadd told analysts this morning that the developer–which ran into a regulatory rejection last year–has been …


Jazz Pharma basks in praise as it adds CNS drugs in Azur acquisition #pharma #services

Posted On Apr 23 2017 by

#azur pharma # Jazz Pharma basks in praise as it adds CNS drugs in Azur acquisition Occasionally cited as a potential takeover target, Jazz Pharmaceuticals ($JAZZ) is in the news this morning with a takeover of its own. The biotech says it has struck an all-stock deal to acquire Dublin, Ireland-based Azur Pharma, adding new CNS drugs to its list of approved drugs. Once the proposed deal goes through, the combined operation is expected to have $475 million in annual revenue. Jazz CEO Bruce Cozadd told analysts this morning that the developer–which ran into a regulatory rejection last year–has been …


Jazz Pharma basks in praise as it adds CNS drugs in Azur acquisition #pharma #chemie

Posted On Apr 14 2017 by

#azur pharma # Jazz Pharma basks in praise as it adds CNS drugs in Azur acquisition Occasionally cited as a potential takeover target, Jazz Pharmaceuticals ($JAZZ) is in the news this morning with a takeover of its own. The biotech says it has struck an all-stock deal to acquire Dublin, Ireland-based Azur Pharma, adding new CNS drugs to its list of approved drugs. Once the proposed deal goes through, the combined operation is expected to have $475 million in annual revenue. Jazz CEO Bruce Cozadd told analysts this morning that the developer–which ran into a regulatory rejection last year–has been …


Jazz Pharma basks in praise as it adds CNS drugs in Azur acquisition #mankind #pharma

Posted On Apr 6 2017 by

#azur pharma # Jazz Pharma basks in praise as it adds CNS drugs in Azur acquisition Occasionally cited as a potential takeover target, Jazz Pharmaceuticals ($JAZZ) is in the news this morning with a takeover of its own. The biotech says it has struck an all-stock deal to acquire Dublin, Ireland-based Azur Pharma, adding new CNS drugs to its list of approved drugs. Once the proposed deal goes through, the combined operation is expected to have $475 million in annual revenue. Jazz CEO Bruce Cozadd told analysts this morning that the developer–which ran into a regulatory rejection last year–has been …


Jazz Pharma basks in praise as it adds CNS drugs in Azur acquisition #pharmaceutical #marketing #companies

Posted On Mar 25 2017 by

#azur pharma # Jazz Pharma basks in praise as it adds CNS drugs in Azur acquisition Occasionally cited as a potential takeover target, Jazz Pharmaceuticals ($JAZZ) is in the news this morning with a takeover of its own. The biotech says it has struck an all-stock deal to acquire Dublin, Ireland-based Azur Pharma, adding new CNS drugs to its list of approved drugs. Once the proposed deal goes through, the combined operation is expected to have $475 million in annual revenue. Jazz CEO Bruce Cozadd told analysts this morning that the developer–which ran into a regulatory rejection last year–has been …


Jazz Pharma basks in praise as it adds CNS drugs in Azur acquisition #fierce #pharma

Posted On Nov 25 2016 by

#azur pharma # Jazz Pharma basks in praise as it adds CNS drugs in Azur acquisition Occasionally cited as a potential takeover target, Jazz Pharmaceuticals ($JAZZ) is in the news this morning with a takeover of its own. The biotech says it has struck an all-stock deal to acquire Dublin, Ireland-based Azur Pharma, adding new CNS drugs to its list of approved drugs. Once the proposed deal goes through, the combined operation is expected to have $475 million in annual revenue. Jazz CEO Bruce Cozadd told analysts this morning that the developer–which ran into a regulatory rejection last year–has been …